- Home
- OMER vs UMAC Comparison
OMER vs UMAC Comparison
Compare OMER & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- UMAC
- Stock Information
- Founded
- OMER 1994
- UMAC 2019
- Country
- OMER United States
- UMAC United States
- Employees
- OMER N/A
- UMAC N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- UMAC
- Sector
- OMER Health Care
- UMAC
- Exchange
- OMER Nasdaq
- UMAC Nasdaq
- Market Cap
- OMER 274.3M
- UMAC 267.7M
- IPO Year
- OMER 2009
- UMAC 2024
- Fundamental
- Price
- OMER $7.61
- UMAC $13.03
- Analyst Decision
- OMER Strong Buy
- UMAC Strong Buy
- Analyst Count
- OMER 6
- UMAC 3
- Target Price
- OMER $27.50
- UMAC $19.33
- AVG Volume (30 Days)
- OMER 8.1M
- UMAC 4.4M
- Earning Date
- OMER 11-12-2025
- UMAC 11-13-2025
- Dividend Yield
- OMER N/A
- UMAC N/A
- EPS Growth
- OMER N/A
- UMAC N/A
- EPS
- OMER N/A
- UMAC N/A
- Revenue
- OMER N/A
- UMAC $7,701,550.00
- Revenue This Year
- OMER N/A
- UMAC $86.94
- Revenue Next Year
- OMER N/A
- UMAC $118.95
- P/E Ratio
- OMER N/A
- UMAC N/A
- Revenue Growth
- OMER N/A
- UMAC 279.38
- 52 Week Low
- OMER $2.95
- UMAC $1.43
- 52 Week High
- OMER $13.60
- UMAC $23.62
- Technical
- Relative Strength Index (RSI)
- OMER 62.09
- UMAC 51.49
- Support Level
- OMER $7.43
- UMAC $11.11
- Resistance Level
- OMER $12.10
- UMAC $13.18
- Average True Range (ATR)
- OMER 0.69
- UMAC 1.63
- MACD
- OMER 0.17
- UMAC -0.37
- Stochastic Oscillator
- OMER 44.09
- UMAC 37.51
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.